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Purpose of review
Breast and ovarian cancer remain a significant burden for
women living in the Western world. This paper reviews the risk
factors and current strategies to prevent these diseases.
Recent findings
Established factors associated with the risk of breast cancer
include family history, reproductive factors and lactation, as well
as age at menarche and menopause. Hormone replacement
therapy increases the risk, whereas oral contraceptives
probably confer no increased risk. Alcohol moderately
increases the risk, whereas a diet rich in folate and carotenoids
might be protective. The role of other dietary factors, smoking
and physical exercise remain unclear. Important risk factors for
ovarian cancer are reproductive factors and possibly the long-
term use of hormone replacement therapy. The risk is
decreased by oral contraceptives. In carriers of a BRCA1 or
BRCA2 gene mutation, prophylactic surgery can significantly
reduce the risk of breast as well as ovarian cancer. Tamoxifen
may be considered as a chemopreventive agent in women with
a high risk of breast cancer, including carriers of a BRCA2
mutation, but is probably not effective in BRCA1 carriers.
Summary
During the period of this review, the importance of several
known risk factors was confirmed, whereas the effects of other
factors became more clear. Chemoprevention and prophylactic
surgery have emerged as preventative options that can reduce
the risk of breast and ovarian cancer.
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Introduction
This paper reviews recent studies (mainly published
since July 2001) on risk factors and risk-reducing
strategies for breast and ovarian cancer. The effective-
ness of screening for breast and ovarian cancer is not
considered in this review and will be discussed else-
where.
Breast cancer
Breast cancer remains the most frequent type of cancer
in women in the world with nearly 1 million new cases
each year worldwide. In most developed countries the
incidence levels are levelling off and, very recently,
declining in some countries, especially in women under
the age of 40 years [1].
With a total of 375 000 deaths each year, it is also the
leading cause of cancer mortality in Europe, and the
second in the United States only after lung cancer [2,3].
Mortality figures have been declining for a number of
years now, and this trend continues, most likely by a
combination of early detection and improved treatment
[3].
Risk factors
Breast cancer is a hormonally related process; most breast
cancer risk factors act through changes in hormonal
(mainly oestrogen) levels that influence the breast
epithelium.
Familial breast cancer
Family history is the most important breast cancer risk
factor. Approximately 5% of all breast cancers are caused
by germline mutations in the BRCA1 and BRCA2 genes.
Evidence of a third breast cancer predisposition gene
was found by a combined investigation of Dutch and
British researchers. They found that mutations in
CHEK-2, a gene involved in DNA repair, account for
approximately 1% of all breast cancers. The clinical
application is still limited as segregation analysis suggests
that the mutation is only expressed in combination with
another, as yet unknown, gene mutation [4..].
Furthermore, two recurrent ATM mutations might be
associated with a nearly 16-fold increased risk compared
with the general population [5..].
Other genetic and environmental factors probably
further modify the risk. A recent review [6] found an
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association for 13 polymorphisms in 10 genes. In
addition, findings from a genetic modelling study [7.]
suggested that several low-penetrance genes rather than
one ‘BRCA3’ gene account for the residual familial
aggregation of breast cancer.
Reproductive factors
Age at first childbirth, parity and age at menarche are
well-known factors that are associated with the risk of
breast cancer. Their strength varies with age at diagnosis
[8].
Placental characteristics might play a role: a large follow-
up study [9.], which started more than 40 years ago,
provided evidence that smaller placentas, maternal floor
infarction and increasing blood pressure during preg-
nancy all reduced the risk of breast cancer. The
protective effect of pre-eclampsia, another marker of
compromised placental function, was already known. A
case–control study in 66 pregnancies with severe pre-
eclampsia and 610 controls [10] suggested that the
possible mechanism might be high levels of alpha-
fetoprotein rather than low levels of oestradiol.
A history of induced abortion appears to have little
influence on the risk of breast cancer, at least in Chinese
women [11].
The effect of breast feeding has long been unclear but
now appears to be firmly established: in addition to
several individual studies, a collaborative re-analysis of
data from 47 studies with a total of 50 302 women with
breast cancer and 96 973 healthy women showed that the
relative risk of breast cancer decreased by 4.3% for each
year of breast feeding [12 .].
Oral contraceptives
The risk of oral contraceptive usage appeared to be
clearly established, with numerous case–control and
cohort studies showing a small increased risk of breast
cancer with long-term usage of oral contraceptives,
especially at a young age. However, a very large study
was recently published that found no association
between current or past use of oral contraceptives and
breast cancer. The study was, with 4575 breast cancer
cases and 4682 controls, large enough to perform
subgroup analyses with respect to long duration of use,
a high dosage of oestrogens, initation at a young age, or a
family history of breast cancer. None of these subgroups
had a significantly increased risk [13 ..].
Hormone replacement therapy
Much publicity was gained by the publication of the
Women’s Health Initiative (WHI) randomized con-
trolled trial, in which women were randomly assigned
between receiving oestrogens plus medroxyprogester-
one acetate (n = 8506) or placebo (n = 8102). In addition
to an excess of cardiovascular disease, the risk of breast
cancer was increased in the treatment arm [hazard ratio
(HR) 1.27; 95% confidence interval (CI) 1.00–1.59].
The trial was terminated early [14..]. The results are
consistent with the (non-significant) 27% increase
found in the Heart and Estrogen Replacement Study
II in postmenopausal women with coronary disease
[15] and estimates from numerous observational studies
suggesting an increased risk, especially of current long-
term use (45 years).
Benign breast disease
The assocation between proliferative breast lesions,
especially atypical hyperplasia, and breast cancer has
long been recognized. The risk of breast cancer in
patients with atypical hyperplasia is approximately equal
in both breasts. Furthermore, the pathological features of
breast cancers developing in women with benign breast
disease, including atypical hyperplasia, do not vary
according to the histology of the previous benign breast
lesion [16]. Together, these findings suggest that these
lesions are risk indicators rather than direct precursors of
breast cancer.
Alcohol and diet
In agreement with many previous studies, a large
prospective study with 1328 incident cases of breast
cancer found that alcohol use moderately increased the
risk of breast cancer [17]. Although the assocation with
the ‘western’ diet (characterized by meat, fat, dairy and
sweets) remains unconfirmed [17,18], a number of
other factors are now consistently associated with the
risk of breast cancer; carotenoids decrease the risk [19]
as well as folate [20]. The risk of low folate intake is
more increased in combination with alcoholic bev-
erages [21].
A decreased risk of soy (phytoestrogens) has only
been established in Chinese women; a case–control
study in Shanghai [22] suggested that regular soy
consumption reduced the risk of breast cancer,
especially for ER/PR-positive tumours. In non-Asian
women phytoestrogens appeared to have little effect
[23].
Smoking
Until recently, studies into the role of active and passive
smoking failed to show an effect of smoking on the risk
of breast cancer. It might be that the contrast in the
comparison of ever versus never smokers was insuffi-
cient. Data from the Nurses’ Health Study were
compatible with a small increased risk of active smoking,
with the highest risks in women initiating smoking
before the age of 17 years. No association with passive
smoking was found [24].
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Anthropometry
It is well known that height and weight are related to
breast cancer. The assocation with weight differs
according to menopausal status. Whereas leanness is
positively associated with premenopausal breast cancer,
overweight (especially visceral) increases the risk of
postmenopausal breast cancer. This was confirmed in a
Canadian case–control study of 1233 incident breast
cancer cases and 1241 controls: a larger waist–hip ratio
and weight gain increase the risk of postmenopausal
breast cancer [25]. Both a Finnish cohort study in 3447
women and a pooled analysis of four case–control studies
[26,27] suggested that the risk of premenopausal breast
cancer is affected early in life; a positive association was
found for tallness during childhood whereas a negative
association was found with body mass index at a young
age.
Physical activity
The evidence remains inconsistent; a case–control study
of 1237 incident cases and 1241 controls suggested that
sustained physical activity throughout life and particu-
larly later in life moderately reduced the risk of breast
cancer [28]. On the other hand, a case–control study of
394 cases and 788 controls showed no assocation with
lifetime physical activity [29]. The reasons for this
inconsistency might be different assessment methods of
physical activity or interaction with other factors. This is
suggested by a Swedish cohort study [30] that found an
association with physical activity only for normal-weight
postmenopausal and overweight premenopausal women.
Environmental factors
A Canadian case–control study found an association with
dioxin-like polychlorinated biphenyls, suggesting that
exposure to these substances might increase the risk of
breast cancer or, alternatively, that cases and controls
have different metabolic pathways involved in the
biotransformation of polychlorinated biphenyls and
oestrogens [31]. P53 mutations might modify this
association [32].
Two studies, a case–control and a cohort [33.,34.], were
published that found a positive association between the
disruption of the diurnal sleep–wakefulness rhythm,
especially during night-shift work and the risk of breast
cancer. The mechanism is unclear but is postulated to be
exposure to light at night, causing a reduced level of
melatonin, a hormone that suppresses ovarian oestrogen
production.
Chronic exposure to residential magnetic fields might
also suppress the nocturnal production of melatonin.
However, no assocation was found in a recent case–
control study with 813 cases and 793 age-matched
controls [35].
Ovarian cancer
Epithelial ovarian cancer is the seventh most frequent
cancer in European women, with 58 000 new cases and
38 000 deaths in 1995 [36]. The incidence is low under
the age of 40 years but increases rapidly after meno-
pause. Despite new chemotherapy agents, the prognosis
remains fairly poor with a 5-year relative survival of 30%
[37].
Risk factors
Many theories have been postulated regarding the
pathogenesis of ovarian cancer. Risk factors are not well
defined, with the exception of parity and oral contra-
ceptive use. Most studies consider the epidemiology of
epithelial ovarian cancer, representing approximately
90% of all ovarian carcinomas.
Hereditary ovarian cancer
Approximately 10% of ovarian cancers are hereditary,
with BRCA1 and BRCA2 explaining the majority
(approximately 90%) of hereditary ovarian cancer cases.
The lifetime risk varies between 15 and 66%, suggesting
the existence of modifying genetic or environmental
factors [38].
Reproductive factors
The protective effects of increasing parity and breast
feeding have been clearly established. Early age at
menarche and late age at menopause increase the risk of
ovarian cancer only modestly, so that it can be assumed
that the length of menstrual life plays no crucial role in
the pathogenesis of the disease [39].
The risk of sub/infertility on the risk of ovarian cancer
has been extensively studied. Most studies use atten-
dance at an infertility clinic as a marker for subfertility.
The difficulty is the differentiation between the
infertility itself and the treatment given at the clinic,
that may in itself increase the risk of ovarian cancer. A
pooled analysis of case–control studies, including 5207
cases and 7705 controls, suggested that specific biologi-
cal causes of infertility rather than fertility drugs
increased the risk of ovarian cancer [40.].
Oral contraceptives
Several studies have consistently shown a decreased risk
of sporadic as well as familial ovarian cancer [41]. The
risk reduction is already apparent after a few months of
use and persists for years after discontinuation. Low-
dose formulations (535 mg ethinyl oestradiol) also
confer a substantial risk reduction [42]. However,
inconsistent results were reported for women at risk of
hereditary ovarian cancer. Although a case–control study
in 207 BRCA1/2 carriers [43] reported a significant 50%
risk reduction, a case–control study in Jewish women
[44 .] found that oral contraceptives significantly
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decreased the risk of ovarian cancer only in non-carriers
but not in carriers of a BRCA1/2 mutation.
Oestrogen/hormone replacement therapy
Hormone replacement therapy (HRT) has been incon-
sistently linked to ovarian cancer. Recently, several
prospective studies [45.,46.] consistently found a small
increased risk, especially for long-term users of oestrogen
replacement therapy. Sequentially rather than continu-
ously added progestins might further increase the risk
[47].
Diet
The evidence remains inconsistent; recent studies
suggest that food items high in carotene and lycopene
might decrease the risk [48], whereas red meat was
associated with an elevated risk [49]. However, all
positive studies were case–control studies, and a recent
prospective study within the Nurses’ Health Study
found no association between the usage of vitamins/
carotenoids and ovarian cancer [50]. It might be that
(part of) the reported associations in previous studies
were caused by the various types of bias (especially
recall bias) that can occur in case–control studies.
Physical activity
It is hypothesized that recreational physical activity may
reduce the risk of ovarian cancer by decreasing oestrogen
levels. However, although this reduced risk was found
by several studies, others found no or even a modest
positive assocation. The most recent study [51], with 327
cases and 3129 controls, reported a small, non-significant,
decrease in risk only for the highest category of recent
vigorous activity.
Use of non-steroidal anti-inflammatory drugs
Non-steroidal anti-inflammatory drugs increase apoptosis
in ovarian cancer cell lines and can inhibit ovulation [52].
In observational studies, the association between com-
monly used anti-inflammatory drugs and ovarian cancer
remains unclear. A Danish cohort study found no
evidence of a protective effect of paracetamol [53], and
a case–control study conducted in the USA concluded
that, although non-significant, the observed risk esti-
mates appeared to be compatible with a small decrease
of risk by regular (more than three times a week for a
period of at least 6 months) aspirin use [54].
Risk reduction
Options to reduce the risk of breast and ovarian cancer
include life-style modification, prophylactic surgery and
chemoprevention.
Life-style modification
Risk factors that are most amenable for primary
prevention are dietary factors (including alcohol), smok-
ing and physical exercise. Although the impact on the
risk of breast and ovarian cancer is either unclear or at
best modest, a healthy life-style with the avoidance of
smoking, moderate usage of alcohol, and physical
exercise is advisable as it might also decrease the risk
of a number of other diseases, such as other cancer types
and cardiovascular disease.
Prophylactic surgery
The short-term potential of prophylactic mastectomy
was clearly demonstrated by a prospective study in 139
BRCA1/2 carriers. Within 3 years’ follow-up, no cases of
breast cancer appeared in 76 women opting for
prophylactic mastectomy and eight occurred in 63
women opting for intensive surveillance [55 ..].
Two complementary studies in BRCA1/2 gene mutation
carriers demonstrated that prophylactic (salpingo-)oo-
phorectomy can reduce the risk of hereditary ovarian as
well as breast cancer. In a prospective study of 170
carriers with a mean follow-up of 2 years [56 ..], one
woman developed peritoneal cancer and three breast
cancer in the salpingo-oophorectomy group of 98
women. Three occult stage I gynaecological tumours
were found at the time of prophylactic surgery. In the
surveillance group of 72 women, five women developed
ovarian or peritoneal cancer and eight developed breast
cancer. The combined HR for breast and gynaecological
cancer was 0.25 (95% CI 0.08–0.74).
In a multicentre retrospective study with a mean follow-
up of almost 9 years [57 ..], 58 out of 292 carriers opting
for surveillance developed ovarian cancer. Among 259
women undergoing prophylactic oophorectomy, two
women developed primary peritoneal cancer (HR 0.04;
95% CI 0.01–0.16). In six women a stage I ovarian cancer
was diagnosed at the time of surgery. Breast cancer was
diagnosed in 60 out of 142 women opting for surveil-
lance compared with 21 out of 99 women in the
oophorectomy group, giving an HR of 0.47 (95% CI
0.29–0.77).
The risk-reducing potential of tubal ligation had already
been shown in sporadic ovarian cancer. In addition, a
matched case–control study in 232 BRCA1/2 carriers with
ovarian cancer and 232 carriers without the disease [58]
showed that the adjusted odds ratio of developing
ovarian cancer was 0.39 (P = 0.002) after tubal ligation.
The biological mechanism is unclear; hypotheses in-
clude the reduction of ovarian blood supply or a
decreased retrograde transport of potential carcinogens
through the fallopian tubes.
Breast cancer chemoprevention
The effect of tamoxifen in reducing the short-term risk
of oestrogen receptor-positive tumours is clearly estab-
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lished. A meta-analysis including updated results of all
four randomized trials showed a significant 38% reduc-
tion in the incidence of breast cancer [59]. Its
chemopreventive potential in BRCA1 mutation carriers,
at increased risk of oestrogen receptor-negative tumours,
is less clear. In a subgroup analysis of 19 BRCA1/2 cases
participating in the National Surgical Adjuvant Breast
and Bowel Project Breast Cancer Prevention Trial
(NSABP-P1), no reduction of breast cancer incidence
in BRCA1 carriers was observed [relative risk (RR) 1.67;
95% CI 0.41–8.0], whereas there was a suggestion of a
benefit in BRCA2 carriers (RR 0.38; 95% CI 0.06–1.56)
[60 .]. The small number of cases warrants replication in
larger datasets. A modelling study estimating the
potential impact of tamoxifen on BRCA1/2 carriers [61]
concluded that the benefit of tamoxifen is likely to be
modest in BRCA1 carriers and might be larger in BRCA2
carriers. Future chemopreventive agents may include
raloxifene, which is now being compared with tamoxifen
in the STAR trial [59].
Ovarian cancer chemoprevention
Oral contraceptives substantially reduce the risk of
sporadic ovarian cancer, so might be an effective
chemopreventive agent in high-risk women. However,
because of the inconsistent results in BRCA1/2 carriers
[43,44 .], it is premature to consider oral contraceptives
for the chemoprevention of hereditary ovarian cancer.
Conclusion
In the period covered in this review, the importance of
several known risk factors for breast and ovarian cancer
was confirmed, whereas the effects of lactation, some
dietary factors and HRT became more clear. In contrast
to previous concerns, oral contraceptives probably confer
no increased risk of breast cancer.
The publication of several prospective studies on the
potential of risk-reducing surgery in BRCA1/2 carriers
provides evidence facilitating decision-making on pre-
ventative strategies in these high-risk women.
Whereas tamoxifen and oral contraceptives may be
considered as chemopreventive agents for the reduction
of the risk of breast and ovarian cancer, respectively,
their potential in reducing the risk of hereditary breast
and ovarian cancer is still unclear.
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